Elite Pharmaceuticals Inc (ELTP) stock
ELTPOTCPharmaceutical PreparationsFiscal year ends March 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 13/30
$0.25−0.00 (-1.37%)
Close on Oct 19, 2026Market cap $283.02MP/E 5.0Yield –
Elite Pharmaceuticals revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Elite Pharmaceuticals's revenue for the twelve months ending Jun 30, 2026 was $141.01M, up 33.7% year over year. For fiscal 2026 it was $148.87M, up 77.1% from the year before. Over ten years it grew 28.1% a year on average. The highest annual figure on record is $148.87M in fiscal 2026.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | $148.87M | +77.1% |
| FY2025 | Mar 31, 2025 | $84.04M | +48.4% |
| FY2024 | Mar 31, 2024 | $56.63M | +65.8% |
| FY2023 | Mar 31, 2023 | $34.16M | +5.9% |
| FY2022 | Mar 31, 2022 | $32.26M | +27.1% |
| FY2021 | Mar 31, 2021 | $25.38M | +41.0% |
| FY2020 | Mar 31, 2020 | $17.99M | +137.8% |
| FY2019 | Mar 31, 2019 | $7.57M | +1.5% |
| FY2018 | Mar 31, 2018 | $7.46M | -22.6% |
| FY2017 | Mar 31, 2017 | $9.64M | -22.9% |
| FY2016 | Mar 31, 2016 | $12.50M | +149.2% |
| FY2015 | Mar 31, 2015 | $5.02M | +9.0% |
| FY2014 | Mar 31, 2014 | $4.60M | +35.2% |
| FY2013 | Mar 31, 2013 | $3.40M | +40.4% |
| FY2012 | Mar 31, 2012 | $2.42M | -43.2% |
| FY2011 | Mar 31, 2011 | $4.27M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | $32.36M | -19.5% |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | $40.75M | +27.4% |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | $31.59M | +119.9% |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | $36.32M | +92.4% |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | $40.21M | +113.9% |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | $32.00M | +78.3% |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | $14.36M | -7.6% |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | $18.88M | +33.4% |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | $18.80M | +109.4% |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | $17.95M | +107.7% |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | $15.54M | +68.0% |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | $14.16M | +64.9% |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | $8.98M | +17.0% |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | $8.64M | +12.6% |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | $9.25M | +3.1% |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | $8.59M | +0.3% |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | $7.67M | +8.7% |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | $7.67M | +74.5% |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | $8.97M | +48.4% |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | $8.56M | +15.7% |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | $7.06M | -6.4% |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | $4.40M | -11.1% |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | $6.05M | +19.6% |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | $7.40M | +59.7% |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | $7.54M | +124.4% |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | $4.95M | +268.0% |
| Q3 FY2020CQ4 2019 | Dec 31, 2019 | $5.06M | +87.6% |
| Q2 FY2020CQ3 2019 | Sep 30, 2019 | $4.63M | +240.0% |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | $3.36M | +55.0% |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | $1.34M | -15.9% |
| Q3 FY2019CQ4 2018 | Dec 31, 2018 | $2.69M | +6.3% |
| Q2 FY2019CQ3 2018 | Sep 30, 2018 | $1.36M | -16.0% |
| Q1 FY2019CQ2 2018 | Jun 30, 2018 | $2.17M | +27.3% |
| Q4 FY2018CQ1 2018 | Mar 31, 2018 | $1.60M | +18.3% |
| Q3 FY2018CQ4 2017 | Dec 31, 2017 | $2.54M | +8.8% |
| Q2 FY2018CQ3 2017 | Sep 30, 2017 | $1.62M | -39.6% |
| Q1 FY2018CQ2 2017 | Jun 30, 2017 | $1.70M | – |
| Q4 FY2017CQ1 2017 | Mar 31, 2017 | $1.35M | – |
| Q3 FY2017CQ4 2016 | Dec 31, 2016 | $2.33M | – |
| Q2 FY2017CQ3 2016 | Sep 30, 2016 | $2.69M | – |
See a number that looks wrong?